Learning objectives: To understand the range of epigenetic modifiers mutated in kidney cancer.
To describe the consequences of SETD2 loss or haploinsufficiency in mitosis.
03/01/2022 - 12:00pm to 1:00pm CST
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
W. Kimryn Rathmell, MD, PhD